Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 3 1

Status

Not yet recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 6Autoimmune Diseases 3Neuromuscular Diseases 1Muscle Weakness 1

Interventions

telitacicept 3fludarabine 3Prednisone 3Cyclophosphamide 3Specimen Handling 2Nivolumab 2Antilymphocyte Serum 2thymoglobulin 1remdesivir 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1cabozantinib 1Vitamin D 1Valsartan 1Pyridostigmine Bromide 1Population Groups 1Platinum Compounds 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Music Therapy 1Melphalan 1Ipilimumab 1Infliximab 1Immunoglobulins, Intravenous 1Hydroxychloroquine 1Fish Oils 1Fatty Acids, Omega-3 1Etoposide 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Autoimmune Diseases × telitacicept × Clear all
NCT05737160 2025-05-23

Study of Telitacicept in Generalized Myasthenia Gravis

RemeGen Co., Ltd.

Phase 3 Completed
114 enrolled

Autoimmune Diseases, Myasthenia Gravis, Muscle Weakness

NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase NA Not yet recruiting
60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

NCT06723548 2024-12-09

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase 4 Not yet recruiting
30 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡